Drug products: Glipizide, Mindiab®
ATC code: A10BB07
Some studies indicate a higher risk of hypoglycemia in women compared to men when treated with antidiabetics, there is lacking evidence for differences in dosing and treatment between men and women for glipizide.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of glipizide have been found.
No studies with a clinically relevant sex analysis regarding the effects of glipizide have been found.
The ACCORD study (Action to Control Cardiovascular Risk in Diabetes) was a randomized, controlled trial designed to test the effect of intensive glucose control compared with standard control on cardiovascular outcomes in patients with type 2 diabetes. The study showed that women had a higher risk of hypoglycemia than men regardless of treatment in general .The risk of hypoglycemia in patients treated with a combination of metformin and glipizide or sitagliptin was evaluated in a German study (694 men, 478 women). In patients treated with metformin and glipizide, more women experienced confirmed or severe hypoglycemia than men . The frequency of hypoglycemia events was investigated in patients 66 years or older using sulfonylureas, i.e. glipizide or glibenclamide (also called glyburide). The participants also filled a prescription for one of the 16 most commonly prescribed antimicrobials for this population (n=44,991 male prescriptions, n=88,544 female prescriptions). There was no significant interaction between patient sex on the odds of subsequent hypoglycemia .
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2020-07-09
Reviewed by: Carl-Olav Stiller
Approved by: Karin Schenck-Gustafsson